PrecisemAb Biotech Participates in BIO 2026 to Expand Global Partnerships and Business Opportunities
PrecisemAb Biotech was pleased to once again participate as part of the Taiwan delegation at BIO…
News
Read MorePrecisemAb Biotech Participates in BIO 2026 to Expand Global Partnerships and Business Opportunities
PrecisemAb Biotech Selected for the Final Pitch of the Inaugural PharmaEssentia Innovation Award, Highlighting the Global Potential of Its Antibody Lock Platform
PrecisemAb Biotech was honored to participate in the final pitch of the inaugural PharmaEssentia Innovation Award…
PrecisemAb Biotech Selected as One of Six Finalists in the SelectUSA Health Tech Pitch
PrecisemAb Biotech is grateful to have completed an intensive and highly rewarding week through SelectUSA and…
PrecisemAb Biotech Congratulates GlycoNex on Advancing GNX201-ADC with Nippon Kayaku, Highlighting the Value of Antibody Lock Technology in Next-Generation ADC Development
PrecisemAb Biotech is pleased to have contributed to the early-stage Antibody Lock design of GNX201 with…
PrecisemAb Biotech Receives SBIR Support to Advance PSM101 Antibody Lock Therapeutic Development
PrecisemAb Biotech is pleased to have been selected for this year’s SBIR Small Business Innovation Research…
PrecisemAb Successfully Develops Universal Antibody Lock to Overcome the Trade Off Between Efficacy and Toxicity in Cancer Therapy
We sincerely thank ESGtimes – Sustainable Times for the interview and in-depth feature, which allows more…
Spatial-hindrance-based pro-Adalimumab prevents anti- idiotypic antibody interference in pharmacokinetic and therapeutic efficacy
Read MoreSpatial-hindrance-based pro-Adalimumab prevents anti- idiotypic antibody interference in pharmacokinetic and therapeutic efficacy
PrecisemAb Awarded the Title of “2025 Emerging High-Potential Startup”
PrecisemAb Biotech has been honored by the Small and Medium Enterprise Administration, Ministry of Economic Affairs,…
PrecisemAb Impresses at US BIO and Bio Asia–Taiwan, Attracting Global Pharma Interest
PrecisemAb Biotech participated in the 2025 US BIO International Convention and Bio Asia–Taiwan, showcasing its Universal…
PrecisemAb Breaks Into the Final Six and Secures the Company First Prize at the 9th Startup Star Competition
PrecisemAb Biotech received the First Prize in the Company Category at the 9th Startup Star Pitch…
Protease-activated anti-Lewis Y antibody enhances selectivity and safety of glycan-targeting cancer therapy
Read MoreProtease-activated anti-Lewis Y antibody enhances selectivity and safety of glycan-targeting cancer therapy
GlycoNex and PrecisemAb Co-Develop an Innovative Pro-Antibody Demonstrating High Tumor Selectivity and Safety; Research Published in an International Journal
PrecisemAb Biotech Co., Ltd. extends its sincere congratulations to the team at GlycoNex Inc.! We are…